Mer­ck board waves off a forced re­tire­ment for CEO Ken Fra­zier, hap­py to ex­tend his reign

Suc­ces­sion plan­ning at Mer­ck $MRK is go­ing on the back burn­er.

Nor­mal­ly, CEO Ken Fra­zier would be prep­ping for the start of his last year at the phar­ma gi­ant. But with Keytru­da bar­rel­ing in­to the lead in the im­muno-on­col­o­gy field as Fra­zier en­joys a hard-won rep for prin­ci­pled lead­er­ship, the board has waved off the com­pa­ny’s manda­to­ry re­tire­ment age of 65.

That big birth­day is loom­ing at the end of next year.

Leslie Brun

“CEO suc­ces­sion has been our top pri­or­i­ty, and re­mov­ing the manda­to­ry re­tire­ment pol­i­cy en­ables the board to make the best de­ci­sion con­cern­ing the tim­ing of that tran­si­tion,” said Leslie Brun, lead di­rec­tor, speak­ing on be­half of the board. “Ken’s un­wa­ver­ing ded­i­ca­tion over the years to Mer­ck’s mis­sion of de­liv­er­ing in­no­v­a­tive med­i­cines and vac­cines has helped dri­ve val­ue for share­hold­ers and pa­tients. We look for­ward to Ken’s con­tin­u­ing lead­er­ship and the im­pact it will have.”

The son of a jan­i­tor and one of the pre­cious few black ex­ec­u­tives in the top ranks of the in­dus­try, Fra­zier gar­nered head­lines a year ago as he pub­licly stood up to the Trump ad­min­is­tra­tion, out­raged by the pres­i­dent’s un­will­ing­ness to con­demn white su­prema­cists in­volved in a dead­ly clash in Vir­ginia. 

Fra­zier re­signed from one of the pres­i­dent’s blue-chip ad­vi­so­ry coun­cils, prompt­ing a quick rip from the pres­i­dent, who en­joys at­tack­ing his op­po­nents — and any­one in Big Phar­ma — on Twit­ter.

Fra­zier earned a com­pen­sa­tion pack­age worth $17.6 mil­lion last year, mak­ing him one of the best paid ex­ec­u­tives in the in­dus­try.

As is of­ten the case in Big Phar­ma­land, Matthew Her­p­er did the hon­ors chron­i­cling Fra­zier’s sto­ry, in­clud­ing his start as a promi­nent at­tor­ney named chief coun­sel at Mer­ck in 1999. Fra­zier’s first big task was fight­ing back against a tsuna­mi of Vioxx law­suits. His sec­ond was bring­ing Roger Perl­mut­ter back to helm R&D just as Keytru­da was emerg­ing as a star play­er. 

That leaves Fra­zier ready to cel­e­brate his 20th an­niver­sary at Mer­ck next year, with no set plans for step­ping down.

Mer­ck chair­man and CEO Ken­neth Fra­zier at­tends the 2018 Time 100 Gala at Jazz at Lin­coln Cen­ter on April 24, 2018 in New York City. GET­TY IM­AGES for TIME

Brian Kaspar. AveXis via Twitter

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

Brian Kaspar’s head was among the first to roll at Novartis after company execs became aware of the fact that manipulated data had been included in its application for Zolgensma, now the world’s most expensive therapy.

But in his first public response, the scientific founder at AveXis — acquired by Novartis for $8.7 billion — is firing back. And he says that not only was he not involved in any wrongdoing, he’s ready to defend his name as needed.

I reached out to Brian Kaspar after Novartis put out word that he and his brother Allen had been axed in mid-May, two months after the company became aware of the allegations related to manipulated data. His response came back through his attorneys.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,700+ biopharma pros reading Endpoints daily — and it's free.

Novartis CEO Vas Narasimhan [via Bloomberg/Getty]

I’m not per­fect: No­var­tis chief Vas Narasimhan al­most apol­o­gizes in the wake of a new cri­sis

Vas Narasimhan has warily stepped up with what might pass as something close to a borderline apology for the latest scandal to engulf Novartis.

But he couldn’t quite get there.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,700+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Pay­back? An­a­lysts say Sarep­ta was blind­sided by an FDA re­jec­tion dri­ven by reg­u­la­to­ry re­venge

In one of the least anticipated moves of the year, the FDA has rejected Sarepta’s application for an accelerated approval of its Duchenne MD drug golodirsen after fretting over safety issues.

In a statement that arrived after the bell on Monday, Sarepta explained the CRL, saying:

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,700+ biopharma pros reading Endpoints daily — and it's free.

FDA de­ci­sion on Ver­tex's CF triple will come just ahead of planned CEO shake­up

Vertex has clinched a priority review for the all-important cystic fibrosis triple that will blaze the trail for treating a large group of patients unhelped by its current drugs.

FDA regulators have set a PDUFA date of March 19, 2020, just a year after the Boston biotech posted positive Phase III results showing that people with two F508del mutations experienced statistically significant improvements in lung function after a 4-week regimen of VX-445, tezacaftor and ivacaftor. After reviewing 24-week data among patients with one F508del mutation and one minimal function mutation — and thoroughly comparing the VX-445 triple with another combo featuring VX-659 on scores like safety, drug-drug interactions, and photosensitivity — Vertex ultimately went with VX-445.

An MIT spin­out kills one of its ‘liv­ing ther­a­peu­tics’ af­ter flunk­ing an ear­ly-stage study — shares rout­ed

Just a few weeks after bagging $80 million in a deal to collaborate with Gingko Bioworks on its special blend of engineered bacteria used for “living therapeutics,” little Synlogic in Boston $SYBX is tossing one of its two clinical programs after watching an early-stage study go down in defeat.

Their Phase Ib/IIa study for SYNB1020 to counter the accumulation of ammonia in the body, a condition called hyperammonemia or urea cycle disorder, floundered at the interim readout, forcing the biotech to kill it and reserve its cash for pipeline therapies with greater potential.

Elan­co to buy Bay­er's an­i­mal health busi­ness for $7.6B, as deal­mak­ing gath­ers steam in the sec­tor

Last week, Elanco explicitly dodged answering questions about its rumored interest in Bayer’s animal health business in its post-earnings call. On Tuesday, the Eli Lilly spinoff disclosed it was purchasing the German drug maker’s veterinary unit in a cash-and-stock deal worth $7.6 billion. 

Elanco $ELAN has been busy on the deal-making front. In April, it laid out plans to swallow its partner, Kansas-based pet therapeutics company Aratana $PETX. A July report by Reuters suggested a potential Bayer deal was being explored, and Bloomberg last week said the deal was imminent, citing sources. 

As­traZeneca's di­a­betes drug Farx­i­ga helps pa­tients with heart dis­ease and with­out di­a­betes in land­mark tri­al

Months ago, data on J&J’s $JNJ Invokana indicated the diabetes drug conferred cardiovascular (CV) benefit in patients who do and do not have preexisting CV disease. On Tuesday, AstraZeneca’s $AZN rival treatment, Farxiga, was shown to cut the risk of CV death or the worsening of heart failure in patients with heart disease, in a landmark trial.

The treatments, in addition to Jardiance from Eli Lilly $LLY, belong to a class of diabetes drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors, which work by curbing the absorption of glucose via the kidneys so that surplus glucose is excreted through urination.

Levi Garraway. Broad Institute via Youtube

Roche raids Eli Lil­ly for its next chief med­ical of­fi­cer as San­dra Horn­ing plans to step down

We found out Monday morning where Levi Garraway was headed after he left Eli Lilly as head of oncology R&D a few days ago. Roche named Garraway as their new chief medical officer, replacing Sandra Horning, who they say is retiring from the company.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,700+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a posse of Wall Street an­a­lysts pre­dict a like­ly new win for Sarep­ta, we're down to the wire on a crit­i­cal FDA de­ci­sion

As Bloomberg notes, most of the Wall Street analysts that cover Sarepta $SRPT are an upbeat bunch, ready to cheer on the team when it comes to their Duchenne MD drugs, or offer explanations when an odd setback occurs — as happened recently with a safety signal that was ‘erroneously’ reported last week.

Ritu Baral Cowen
Endpoints News

Basic subscription required

Unlock this story instantly and join 57,700+ biopharma pros reading Endpoints daily — and it's free.